Anemia Indication Sought for Phosphate Binder
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Phosphate Binders
Study: Phosphate Binders Do Not Lower Death Risk
Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.
Uncontrolled Phosphorus Linked to Poor Binder Adherence
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
Sucroferric Oxyhydroxide Exhibits a Dose-Dependent Effect
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Even High-Normal Phosphorus May Be an ESRD Risk Factor, Study Finds
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Young Patients Often Misperceive Adherence to Phosphorus Control
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Patient Autonomy May Improve Phosphate Binder Adherence
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
Calcium-based Phosphate Binders Linked to Higher Mortality
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
Iron-Based Binder Found to Improve Phosphorus Control, Cut Pill Burden
Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.
Fixed-Dose Phosphate Binder Schedules May Be Less Than Ideal
Study of peritoneal dialysis patients showed that they do not adjust binders to match the phosphate content of meals and snacks.
- Loading...
Loading...
Next post in Hyperphosphatemia
Loading... 
Loading...